Abstract
A conspicuous feature shared by Alzheimers disease as well as a variety of highly prevalent, clinically unrelated neurodegenerative disorders is the occurrence of protein aggregates both intra- and extracellularly. Most of these conditions are characterized at autopsy by the presence of such deposits, typically of fibrillar structure and accompanying extensive neuronal cell loss, displaying a selective brain distribution. The recently discovered similarities of a number of these aggregates with a novel type of experimentally induced protein deposit, formed as a general response to discrepancies in protein turnover and designated the “aggresome”, has prompted speculations about the involvement of the ubiquitin-proteasome system in a process fundamental to neurodegeneration. Consistent with this view, protein aggregates have been regarded in a pathogenic connotation, with most aspects of neurologic pathogenesis being largely attributed to their presence in nerve tissues. However, the neurotoxicity of protein aggregates remains ambiguous as direct evidence substantiating it have long remained elusive. A convergence of evidence now support the notion that the actual culprits might comprise the oligomeric, non-fibrillar intermediates that arise early during the aggregation process, termed protofibrils and that the fibrillar end-stage aggregates themselves might actually serve a neuroprotective function. These intermediates ostensibly resolve many puzzling aspects of neurodegeneration and there is evidence that neurotoxicity is one key operational property they may possess. The above attest to the fact that protein aggregation remains a complex issue with a role far more enigmatic than originally thought but nonetheless important for the understanding of the pathological basis of neurodegenerative disorders.
Keywords: ad, sp, nft, aggregate, homeostasis, ros, ups, aggresome
Current Alzheimer Research
Title: Protein Aggregation in Alzheimers Disease and Other Neoropathological Disorders
Volume: 2 Issue: 1
Author(s): Aristotelis C. Dimakopoulos
Affiliation:
Keywords: ad, sp, nft, aggregate, homeostasis, ros, ups, aggresome
Abstract: A conspicuous feature shared by Alzheimers disease as well as a variety of highly prevalent, clinically unrelated neurodegenerative disorders is the occurrence of protein aggregates both intra- and extracellularly. Most of these conditions are characterized at autopsy by the presence of such deposits, typically of fibrillar structure and accompanying extensive neuronal cell loss, displaying a selective brain distribution. The recently discovered similarities of a number of these aggregates with a novel type of experimentally induced protein deposit, formed as a general response to discrepancies in protein turnover and designated the “aggresome”, has prompted speculations about the involvement of the ubiquitin-proteasome system in a process fundamental to neurodegeneration. Consistent with this view, protein aggregates have been regarded in a pathogenic connotation, with most aspects of neurologic pathogenesis being largely attributed to their presence in nerve tissues. However, the neurotoxicity of protein aggregates remains ambiguous as direct evidence substantiating it have long remained elusive. A convergence of evidence now support the notion that the actual culprits might comprise the oligomeric, non-fibrillar intermediates that arise early during the aggregation process, termed protofibrils and that the fibrillar end-stage aggregates themselves might actually serve a neuroprotective function. These intermediates ostensibly resolve many puzzling aspects of neurodegeneration and there is evidence that neurotoxicity is one key operational property they may possess. The above attest to the fact that protein aggregation remains a complex issue with a role far more enigmatic than originally thought but nonetheless important for the understanding of the pathological basis of neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Dimakopoulos C. Aristotelis, Protein Aggregation in Alzheimers Disease and Other Neoropathological Disorders, Current Alzheimer Research 2005; 2 (1) . https://dx.doi.org/10.2174/1567205052772795
DOI https://dx.doi.org/10.2174/1567205052772795 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging
The thematic issue, Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging, aims to bridge the gap between advanced computational techniques and clinical practice in Alzheimer’s disease research. Alzheimer’s disease poses significant challenges in early diagnosis, disease progression monitoring, and predicting treatment efficacy. ...read more
Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies
The increasing burden of age-related neurodegenerative diseases demands an immediate and pressing need for research in all aspects, from molecular mechanisms to therapeutic interventions. The special issue in Current Alzheimer Research "Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies" aims to highlight the summary of state-of-the-art ...read more
Leading Alzheimer Disease Prevention with Precision Health Strategies.
The rising number of patients with Alzheimer’s disease (AD) is a concerning reality in our society. Despite tremendous public-private efforts, finding an appropriate treatment for Alzheimer’s disease prevention has not been successful. One of the reasons behind this failure is the urge to find “a treatment that fits all sizes”, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TAU Aggregation is a Therapeutic Target for Alzheimers Disease
Current Alzheimer Research How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes?
Current Women`s Health Reviews The Role of Mitochondrial Function in Glutamate-Dependent Metabolism in Neuronal Cells
Current Pharmaceutical Design Systemic Inflammation, Infection, ApoE Alleles, and Alzheimer Disease: A Position Paper
Current Alzheimer Research A Simple Principle for Understanding the Combined Cellular Protein Folding and Aggregation
Current Protein & Peptide Science Renin-angiotensin System Blockers and Modulation of Radiation-Induced Brain Injury
Current Drug Targets Signaling Mechanisms Underlying Aβ Toxicity: Potential Therapeutic Targets for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Dysregulation of Acetylation Enzymes Inanimal Models of Psychostimulant use Disorders: Evolving Stories
Current Neuropharmacology Psychedelic 5-Methoxy-N,N-Dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions
Current Drug Metabolism Age-Related Sleep Changes and its Implication in Neurodegenerative Diseases
Current Aging Science Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Current Medicinal Chemistry Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders
Current Neuropharmacology Receptor to Glutamate NMDA-Type: The Functional Diversity of the NR1 Isoforms and Pharmacological Properties
Current Pharmaceutical Design Indoles and Related Compounds as Cannabinoid Ligands
Mini-Reviews in Medicinal Chemistry Remodeling Chromatin and Stress Resistance in the Central Nervous System: Histone Deacetylase Inhibitors as Novel and Broadly Effective Neuroprotective Agents
Current Drug Targets - CNS & Neurological Disorders Defining Primary and Secondary Progenitor Disorders in the Brain: Proteomic Approaches for Analysis of Neural Progenitor Cells
Current Pharmaceutical Biotechnology On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress
Current Pharmaceutical Design Clinical Trajectories and Biological Features of Primary Progressive Aphasia (PPA)
Current Alzheimer Research Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design